BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ATSConferenceNews.org - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ATSConferenceNews.org
X-ORIGINAL-URL:https://www.atsconferencenews.org
X-WR-CALDESC:Events for ATSConferenceNews.org
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T110500
DTEND;TZID=America/New_York:20260517T113500
DTSTAMP:20260408T052717
CREATED:20260401T175503Z
LAST-MODIFIED:20260401T182207Z
UID:10000419-1779015900-1779017700@www.atsconferencenews.org
SUMMARY:An adaptive clinical study programme with IKT-001 for Pulmonary Arterial Hypertension
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/an-adaptive-clinical-study-programme-with-ikt-001-for-pulmonary-arterial-hypertension/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T113000
DTEND;TZID=America/New_York:20260517T123000
DTSTAMP:20260408T052717
CREATED:20260401T175158Z
LAST-MODIFIED:20260401T175158Z
UID:10000390-1779017400-1779021000@www.atsconferencenews.org
SUMMARY:Clinical Evidence in Severe Asthma: A New Biologic Option for Patients with an Eosinophilic Phenotype
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/clinical-evidence-in-severe-asthma-a-new-biologic-option-for-patients-with-an-eosinophilic-phenotype/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T113000
DTEND;TZID=America/New_York:20260517T123000
DTSTAMP:20260408T052717
CREATED:20260401T175159Z
LAST-MODIFIED:20260403T185233Z
UID:10000391-1779017400-1779021000@www.atsconferencenews.org
SUMMARY:An Overview of JASCAYD®  (nerandomilast) tablets for the Clinician
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/an-overview-of-jascayd%c2%acae-nerandomilast-tablets-for-the-clinician/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T113500
DTEND;TZID=America/New_York:20260517T115500
DTSTAMP:20260408T052717
CREATED:20260401T175500Z
LAST-MODIFIED:20260401T175500Z
UID:10000416-1779017700-1779018900@www.atsconferencenews.org
SUMMARY:Chronic cough neuropathic mechanisms and treatment opportunities
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/chronic-cough-neuropathic-mechanisms-and-treatment-opportunities/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T114500
DTEND;TZID=America/New_York:20260517T123000
DTSTAMP:20260408T052717
CREATED:20260401T175159Z
LAST-MODIFIED:20260401T175159Z
UID:10000392-1779018300-1779021000@www.atsconferencenews.org
SUMMARY:Taking Control: The Urgent Need to Identify and Address Uncontrolled Asthma
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/taking-control-the-urgent-need-to-identify-and-address-uncontrolled-asthma-2/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T115500
DTEND;TZID=America/New_York:20260517T121500
DTSTAMP:20260408T052717
CREATED:20260401T175503Z
LAST-MODIFIED:20260401T182207Z
UID:10000420-1779018900-1779020100@www.atsconferencenews.org
SUMMARY:Tuning into Cough in Respiratory Diseases: How Do We Address the Gap?
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/tuning-into-cough-in-respiratory-diseases-how-do-we-address-the-gap/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T120000
DTEND;TZID=America/New_York:20260517T123000
DTSTAMP:20260408T052717
CREATED:20260313T164416Z
LAST-MODIFIED:20260401T183218Z
UID:10000373-1779019200-1779021000@www.atsconferencenews.org
SUMMARY:Reconsidering the Diagnosis: Could it be CF?
DESCRIPTION:Innovation Theater 8 (Mini) | Supported By: Vertex Pharmaceuticals Incorporated \n\n\n\n\n\n\n\nProgram Description\n\n\n\nThis program will review CF prevalence and unique aspects of the diagnosis of CF across racial and ethnic groups\, how CF can present atypically as other idiopathic respiratory conditions including bronchiectasis\, when to reconsider a prior diagnosis\, and the criteria used to establish the diagnosis of CF. In addition\, we will review the impact of a delayed diagnosis on long-term patient outcomes. For the discussion section\, Dr. Solomon will review a case study of CF diagnosis in a patient previously misdiagnosed to highlight diagnostic challenges. \n\n\n\nThis program was developed by Vertex Pharmaceuticals Incorporated and is neither sponsored by nor endorsed by ATS and does not offer CME/CE credit. Vertex and the Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated.  \n\n\n\n©2026 Vertex Pharmaceuticals Incorporated \n\n\n\nSpeaker\n\n\n\nPresenter: George M Solomon\, M.D.Marnix E. Heersink School of MedicineDivision of Pulmonary\, Allergy and Critical Care MedicineM.D.Birmingham Alabama
URL:https://www.atsconferencenews.org/event/sl000025986/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T121500
DTEND;TZID=America/New_York:20260517T123500
DTSTAMP:20260408T052717
CREATED:20260401T175500Z
LAST-MODIFIED:20260403T190550Z
UID:10000417-1779020100-1779021300@www.atsconferencenews.org
SUMMARY:One Scan\, Two Functions: Bringing Non-Contrast Ventilation–Perfusion Mapping into Everyday CT Practice
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/one-scan-two-functions-bringing-non-contrast-ventilationaiperfusion-mapping-into-everyday-ct-practice/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T123000
DTEND;TZID=America/New_York:20260517T130000
DTSTAMP:20260408T052717
CREATED:20260401T175258Z
LAST-MODIFIED:20260407T165516Z
UID:10000393-1779021000-1779022800@www.atsconferencenews.org
SUMMARY:An In-Depth Discussion of Biologic Clinical Trial Data in COPD
DESCRIPTION:Innovation Theater 1 | Supported By: Regeneron and Sanofi \n\n\n\n\n\n\n\nProgram Description\n\n\n\nThis session will examine evidence for targeting a source of type 2 inflammation in inadequately controlled COPD patients with an eosinophilic phenotype. Clinical trial results will be discussed\, including exacerbations\, lung function\, and quality of life outcomes. Participants will also explore considerations for identifying appropriate patients in clinical practice. \n\n\n\nINDICATIONS\n\n\n\nAsthma: DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.Chronic Obstructive Pulmonary Disease: DUPIXENT is indicated as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm. \n\n\n\nIMPORTANT SAFETY INFORMATION\n\n\n\nCONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients. \n\n\n\nWARNINGS AND PRECAUTIONS \n\n\n\nHypersensitivity: Hypersensitivity reactions\, including anaphylaxis\, serum sickness or serum sickness-like reactions\, angioedema\, generalized urticaria\, rash\, erythema nodosum\, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs\, institute appropriate therapy and discontinue DUPIXENT. \n\n\n\nConjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in COPD subjects who received DUPIXENT versus placebo. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings. Some patients reported visual disturbances (e.g.\, blurred vision) associated with conjunctivitis or keratitis. Advise patients or their caregivers to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis\, as appropriate. \n\n\n\nEosinophilic Conditions: Patients being treated for asthma may present with clinical features of eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis (EGPA). These events may be associated with the reduction of oral corticosteroid therapy. Healthcare providers should be alert to vasculitic rash\, worsening pulmonary symptoms\, cardiac complications\, kidney injury\, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adults who participated in the asthma development program and cases of EGPA have been reported with DUPIXENT in adults who participated in the asthma development program as well as in adult subjects with co-morbid asthma in the CRSwNP development program. Advise patients to report signs of eosinophilic pneumonia and EGPA. Consider withholding DUPIXENT if eosinophilic pneumonia or EGPA are suspected. \n\n\n\nAcute Symptoms of Asthma or Chronic Obstructive Pulmonary Disease or Acute Deteriorating Disease: Do not use DUPIXENT to treat acute symptoms or acute exacerbations of asthma or COPD\, acute bronchospasm\, or status asthmaticus. Patients should seek medical advice if their asthma or COPD remains uncontrolled or worsens after initiation of DUPIXENT.Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic\, topical\, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose\, if appropriate\, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. \n\n\n\nPatients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians. \n\n\n\nPsoriasis: Cases of new-onset psoriasis have been reported with the use of DUPIXENT for the treatment of asthma\, including in patients without a family history of psoriasis. In postmarketing reports\, these cases resulted in partial or complete resolution of psoriasis with discontinuation of dupilumab\, with or without use of supplemental treatment for psoriasis (topical or systemic). Those who continued dupilumab received supplemental treatment for psoriasis to improve associated symptoms. Advise patients to report new-onset psoriasis symptoms. If symptoms persist or worsen\, consider dermatologic evaluation and/or discontinuation of DUPIXENT. \n\n\n\nArthralgia and Psoriatic Arthritis: Arthralgia has been reported with use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Cases of new-onset psoriatic arthritis requiring systemic treatment have been reported with the use of DUPIXENT. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen\, consider rheumatological evaluation and/or discontinuation of DUPIXENT. \n\n\n\nParasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment\, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT. \n\n\n\nADVERSE REACTIONS:\n\n\n\nMost common adverse reactions are:Asthma (incidence ≥1%): injection site reactions\, oropharyngeal pain\, and eosinophilia.Chronic Obstructive Pulmonary Disease (incidence ≥2%): viral infection\, headache\, nasopharyngitis\, back pain\, diarrhea\, arthralgia\, urinary tract infection\, local administration reactions\, rhinitis\, eosinophilia\, toothache\, and gastritis. \n\n\n\nUSE IN SPECIFIC POPULATIONS \n\n\n\n\nPregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects\, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore\, DUPIXENT may be transmitted from the mother to the developing fetus.\n\n\n\nLactation: There are no data on the presence of DUPIXENT in human milk\, the effects on the breastfed infant\, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.\n\n\n\n\nPlease see accompanying full Prescribing Information \n\n\n\nSpeakers:\n\n\n\nPresenter: Thinesh Dahanayake\, MDPulmonary Physicians of NorwichMedical DirectorNorwich\, Connecticut
URL:https://www.atsconferencenews.org/event/sl000025749/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T123500
DTEND;TZID=America/New_York:20260517T125500
DTSTAMP:20260408T052717
CREATED:20260401T175504Z
LAST-MODIFIED:20260401T182207Z
UID:10000421-1779021300-1779022500@www.atsconferencenews.org
SUMMARY:ESI with Spirometry
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/esi-with-spirometry/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T125500
DTEND;TZID=America/New_York:20260517T131500
DTSTAMP:20260408T052717
CREATED:20260401T175503Z
LAST-MODIFIED:20260401T182206Z
UID:10000418-1779022500-1779023700@www.atsconferencenews.org
SUMMARY:Empowering Discovery with Standardized In Vitro Lung Models
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/empowering-discovery-with-standardized-in-vitro-lung-models/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T130000
DTEND;TZID=America/New_York:20260517T134500
DTSTAMP:20260408T052717
CREATED:20260316T220307Z
LAST-MODIFIED:20260401T183231Z
UID:10000375-1779022800-1779025500@www.atsconferencenews.org
SUMMARY:Beyond the Airway: Conversations That Shape Severe Asthma Treatment Decisions
DESCRIPTION:Innovation Theater 4 | Supported By: GSK \n\n\n\n\n\n\n\nProgram Description\n\n\n\nThrough live clinician–patient dialogue\, this session will explore real-world factors that shape treatment decision-making and long-term management in severe asthma. Despite advances in therapy\, care is often influenced by challenges that extend beyond the airway\, including clinical complexity\, treatment burden\, and patient preferences. \n\n\n\nThe conversation will focus on how practical considerations\, ranging from individual lifestyle demands and patient preferences to health disparities\, inform clinical decisions. Shared decision-making will be highlighted as a critical framework for meaningful\, patient-centered conversations that align clinical objectives with what matters most to patients. By bringing clinician-patient perspectives to the forefront\, this session aims to offer practical insights into optimizing severe asthma care through intentional\, collaborative treatment discussions that support sustained asthma management. \n\n\n\nSpeakers\n\n\n\nPresenter: Njira L Lugogo\, MD\, MSUniversity of Michigan HealthPulmonary & Critical Care MedicineClinical ProfessorAnn Arbor\, Michigan \n\n\n\nPresenter: Diego J Maselli\, MD\, FCCP\, ATSFUT Health at San AntonioDivision of Pulmonary Diseases & Critical CareProfessor and ChiefSan Antonio\, Texas
URL:https://www.atsconferencenews.org/event/sl000025734/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T130000
DTEND;TZID=America/New_York:20260517T140000
DTSTAMP:20260408T052717
CREATED:20260401T175259Z
LAST-MODIFIED:20260403T214009Z
UID:10000394-1779022800-1779026400@www.atsconferencenews.org
SUMMARY:Advancements in Alpha-1 Antitrypsin Deficiency (AATD): Aiming for AAT Restoration and ​Clinically Meaningful Endpoints
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/advancements-in-alpha-1-antitrypsin-deficiency-aatd-aiming-for-aat-restoration-and-aa-clinically-meaningful-endpointsaa/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T131500
DTEND;TZID=America/New_York:20260517T133500
DTSTAMP:20260408T052717
CREATED:20260401T175504Z
LAST-MODIFIED:20260401T182208Z
UID:10000422-1779023700-1779024900@www.atsconferencenews.org
SUMMARY:FeNO in Practice: Current Applications and Emerging Opportunities
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/feno-in-practice-current-applications-and-emerging-opportunities/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T131500
DTEND;TZID=America/New_York:20260517T140000
DTSTAMP:20260408T052717
CREATED:20260324T172429Z
LAST-MODIFIED:20260401T183247Z
UID:10000377-1779023700-1779026400@www.atsconferencenews.org
SUMMARY:The Duality of IL-33 in COPD: Inflammation and Mucus Dysfunction with Dr Monica Kraft\, MD
DESCRIPTION:Innovation Theater 5 | Supported By: AstraZeneca \n\n\n\n\n\n\n\nProgram Description\n\n\n\nIs there more than one way to think about IL-33 in COPD? \n\n\n\nPlease join Monica Kraft\, MD\, for an engaging presentation discussing how the dual pathways of interleukin-33 (IL-33) may contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). \n\n\n\nInflammation\, epithelial damage\, and mucus dysfunction are central features of COPD. IL-33 is a cytokine expressed in the lung and released in response to epithelial injury. Two bioactive forms of IL-33 have been described\, a reduced form and an oxidized form\, which play distinct roles in driving inflammatory pathways and mucus dysfunction in COPD\, respectively. \n\n\n\nThis session will explore: \n\n\n\n\nIL-33\, a cytokine that can drive a broad spectrum of downstream host-response mechanisms in COPD\n\n\n\nThe role of reduced IL-33 (IL-33 RED) as a driver of inflammation\n\n\n\nA novel mechanism in which oxidized IL-33 (IL-33 OX) drives airway epithelial damage and mucus dysfunction\n\n\n\nHow dysregulation of the IL-33 pathways is associated with biological mechanisms of COPD and their potential clinical impact\n\n\n\n\nDr Monica Kraft is an internationally known physician-scientist who specializes in clinical and translational research in airway disease. She serves as System Chair of the Samuel Bronfman Department of Medicine\, Murray M. Rosenberg Professor of Medicine\, and Associate Dean for Clinical Affairs at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System. Dr Kraft’s work has appeared in journals such as The New England Journal of Medicine\, The Journal of the American Medical Association\, The Lancet\, The Journal of Immunology\, American Journal of Respiratory and Critical Care Medicine\, and The Journal of Allergy and Clinical Immunology. \n\n\n\nReady to take a deeper dive into the pathobiology of inflammation and mucus dysfunction in COPD? \n\n\n\nDiscover the duality of IL-33 in COPD. \n\n\n\nUS-109691 Last Updated 3/26 \n\n\n\nSpeakers\n\n\n\nPresenter: Monica Kraft\, MDMount Sinai HealthSystem Chair and Associate DeanNew York\, New York
URL:https://www.atsconferencenews.org/event/sl000026295/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T133000
DTEND;TZID=America/New_York:20260517T141500
DTSTAMP:20260408T052717
CREATED:20260401T175259Z
LAST-MODIFIED:20260403T185550Z
UID:10000395-1779024600-1779027300@www.atsconferencenews.org
SUMMARY:Evidence Expedition: An Interactive Journey Through Clinical Data For AIRSUPRA®  (albuterol 90 mcg/budesonide 80 mcg)
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/evidence-expedition-an-interactive-journey-through-clinical-data-for-airsupra%c2%acae-albuterol-90-mcg-budesonide-80-mcg/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T183000
DTEND;TZID=America/New_York:20260517T194500
DTSTAMP:20260408T052717
CREATED:20260324T175956Z
LAST-MODIFIED:20260406T183804Z
UID:10000378-1779042600-1779047100@www.atsconferencenews.org
SUMMARY:Turning Down the Inflammatory Signal in COPD: Advancing Care With Biologic Therapies Targeting Upstream Cytokines
DESCRIPTION:Hyatt Regency Orlando\, Windemere Ballroom X (Conference Level) | Provided By: PVI\, PeerView Institute for Medical Education \n\n\n\n\n\n\n\nProgram Description\n\n\n\nChronic obstructive pulmonary disease (COPD) encompasses a group of progressive and inflammatory lung diseases characterized by persistent respiratory symptoms and exacerbations resulting in decreased quality of life (QOL)\, hospitalization\, irreversible lung damage\, and progressively declining lung function. Conventional COPD treatment includes inhaled long-acting bronchodilators and steroids\, but many patients continue to experience poor symptom control and frequent exacerbations. \n\n\n\nTherapeutic advancements have significantly transformed COPD care\, with biologics—initially developed for type 2 inflammatory diseases like asthma—now being repurposed to target these shared type 2 inflammatory pathways in COPD. However\, currently approved biologic therapy in COPD only targets eosinophilic inflammation\, which accounts for a small subpopulation of patients with COPD. Fortunately\, groundbreaking advances identified an upstream target—ST2/IL33—potentially impacting both eosinophilic and neutrophilic inflammation in COPD; this will provide opportunities for personalizing treatment and overcoming limitations of current therapies in a broader patient population (eg\, patients with low eosinophils). \n\n\n\nWith the goal of helping clinicians adapt their practice in alignment with the growing role of biologics in the COPD treatment armamentarium\, PeerView has prepared this Peer Pressure educational symposium. Our panel will discuss the latest data on integrating targeted biologics into updated treatment protocols and recent evidence on emerging options\, factoring in safety\, patient preferences\, and QOL for patients with COPD. In this lively format\, the experts will be put on the spot with clinical questions that spark spirited discussion\, reveal key insights\, and offer real-world guidance. Join us live—in Orlando or online—and see if you can keep up! \n\n\n\nThis CME/MOC/AAPA activity is provided by PVI\, PeerView Institute for Medical Education\, and supported by an educational grant from Genentech\, a member of the Roche Group. \n\n\n\n\nPeerView.com/COPD26Orlando-Join\n\n\n\n\nSpeakers\n\n\n\nChair & Moderator: Cedric “Jamie” Rutland\, MDIM\, Pulmonary and Critical CareNational Spokesperson\, American Lung AssociationRutland Medical Group\, CEO and Medical DirectorMedicine Deconstructed Productions\, PresidentNewport Beach\, California \n\n\n\nPresenter: Stephanie Christenson\, MD\, MASAssociate Professor of MedicineDivision of Pulmonary\, Critical Care\, Allergy\, and Sleep MedicineUniversity of California\, San FranciscoSan Francisco\, California \n\n\n\nPresenter: MeiLan K. Han\, MD\, MSChief\, Pulmonary & Critical CareUniversity of MichiganAnn Arbor\, Michigan \n\n\n\nPresenter: Vickram Tejwani\, MDAssistant ProfessorDepartments of Pulmonary and Critical Care MedicineGenomic Science and Systems BiologyCleveland Clinic Lerner College of MedicineCleveland\, Ohio
URL:https://www.atsconferencenews.org/event/sl000026403/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T183000
DTEND;TZID=America/New_York:20260517T200000
DTSTAMP:20260408T052717
CREATED:20260331T185349Z
LAST-MODIFIED:20260403T191830Z
UID:10000382-1779042600-1779048000@www.atsconferencenews.org
SUMMARY:Look Beyond COPD & Severe Asthma: The Role of AAT Protein in Lung Health
DESCRIPTION:Ballroom R | Supported By: Sanofi \n\n\n\n\n\n\n\nProgram Description\n\n\n\nAlpha-1 antitrypsin deficiency (AATD)\, characterized by insucient protective levels of the AAT protein in the lung\, can contribute to progressive\, irreversible lung damage—particularly when combined with environmental exposures. This session reviews the clinical risks associated with low AAT levels and their potential impact on long-term pulmonary outcomes\, as well as the importance of earlier screening and diagnosis eorts. \n\n\n\nSpeakers\n\n\n\nPresenter: Kyle Hogarth\, MD\, FCCPUniversity of Chicago MedicineProfessor of MedicineChicago\, Illinois
URL:https://www.atsconferencenews.org/event/sl000026434/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T183000
DTEND;TZID=America/New_York:20260517T200000
DTSTAMP:20260408T052717
CREATED:20260403T181902Z
LAST-MODIFIED:20260403T181902Z
UID:10000434-1779042600-1779048000@www.atsconferencenews.org
SUMMARY:A Discussion on JASCAYD® (nerandomilast) tablets
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/a-discussion-on-jascayd-nerandomilast-tablets/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T183000
DTEND;TZID=America/New_York:20260517T203000
DTSTAMP:20260408T052717
CREATED:20260331T180317Z
LAST-MODIFIED:20260403T194850Z
UID:10000379-1779042600-1779049800@www.atsconferencenews.org
SUMMARY:Illuminating Pathways in Epithelial-Driven Inflammation: Evolving Management of Upper and Lower Airway Diseases
DESCRIPTION:Hilton Orlando – Florida Ballroom 1-4 | Supported By: An educational grant from AstraZeneca \n\n\n\n\n\n\n\nProgram Description\n\n\n\nJoin us for dinner and a dynamic Mechanisms to Medicine symposium featuring expert panelists Drs. Joseph Han\, Flavia Hoyte\, and Nizar Jarjour as they examine evolving management approaches for epithelial cytokine–driven inflammatory diseases of the upper and lower airways. This program brings together multidisciplinary perspectives from pulmonology\, allergy and immunology\, and otorhinolaryngology to explore shared underlying disease mechanisms in asthma\, chronic rhinosinusitis with nasal polyps (CRSwNP)\, and chronic obstructive pulmonary disease (COPD). \n\n\n\nThe engaging faculty panel will guide participants through an examination of epithelial cytokine signaling in airway diseases and practical therapeutic decision-making involving new and emerging biologic therapies that target these shared upstream mechanisms. Through a focused Whiteboard animation\, case-based checkpoints\, and interactive faculty dialogue\, learners will examine how epithelial alarmins such as thymic stromal lymphopoietin (TSLP)\, interleukin-25 (IL-25)\, and interleukin-33 (IL-33) drive inflammation\, airway dysfunction\, and disease persistence. \n\n\n\nAttendees will also learn about the latest clinical evidence for newer and emerging biologic therapies that target upstream epithelial cytokine signaling and discuss how to incorporate these novel therapies into mechanism-based treatment strategies\, with an emphasis on optimizing disease control\, reducing oral corticosteroid use\, and improving outcomes across the unified airway. \n\n\n\nThis program was developed by\, or with financial support and influence from\, Integritas Communications and is neither sponsored by nor endorsed by ATS. \n\n\n\n\nREGISTER NOW!\n\n\n\n\nSpeakers\n\n\n\nPresenter: Nizar Jarjour\, MD\, ATSFUniversity of Wisconsin School of Medicine and Public HealthOvid Meyer Endowed Professor of MedicineMadison\, Wisconsin \n\n\n\nPresenter: Joseph Han\, MD\, FARS\, FAAOAEastern Virginia Medical SchoolProfessor of OtolaryngologyNorfolk\, Virginia \n\n\n\nPresenter: Flavia Hoyte\, MDNational Jewish Health/University of ColoradoDivision of Allergy and ImmunologyProfessor of MedicineDenver\, Colorado
URL:https://www.atsconferencenews.org/event/sl000026503/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T183000
DTEND;TZID=America/New_York:20260517T203000
DTSTAMP:20260408T052717
CREATED:20260331T181712Z
LAST-MODIFIED:20260406T145439Z
UID:10000380-1779042600-1779049800@www.atsconferencenews.org
SUMMARY:Gaining Control of Eosinophilic Disorders: Best Practices for Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis
DESCRIPTION:Rosen Center (Room: Executive H) | Supported By: An educational grant from AstraZeneca \n\n\n\n\n\n\n\nProgram Description \n\n\n\nEosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are both rare types of eosinophilic disorders. Diagnosis and management of these disorders is challenging due to their complex and overlapping pathologic features and heterogeneous systemic involvement. Both disorders carry substantial risks of morbidity and mortality due to delayed diagnosis and inadequate treatment. Interleukin (IL)-5 is a key driver of pathophysiology; therapies targeting IL-5 or the IL-5 receptor are a mainstay of treatment. \n\n\n\nIn this confidence-based clinical decision CALIBRATE symposium\, Drs. Praveen Akuthota\, Philip Seo\, and Michael Wechsler will discuss EGPA and HES patient cases with real-world\, point-of-care decision checkpoints paired with confidence ratings to improve diagnosis and treatment sequencing. \n\n\n\nJoin us for dinner on SUN 5/17 6:30 PM at the Rosen Center (Executive H) \n\n\n\n\nREGISTER NOW\n\n\n\nClinical Resource Center\n\n\n\n\nThis program was developed by\, or with financial support and influence from\, Integritas Communications and is neither sponsored by nor endorsed by ATS. \n\n\n\nSpeakers\n\n\n\nPresenter: Michael Wechsler\, MD\, MMScNational Jewish HealthDepartment of MedicineProfessorDenver\, Colorado \n\n\n\nPresenter: Praveen Akuthota\, MDUniversity of California San DiegoProfessor of MedicineLa Jolla\, California \n\n\n\nPresenter: Philip Seo\, MD\, MHSJohns Hopkins University School of MedicineAssociate Professor of MedicineBaltimore Maryland
URL:https://www.atsconferencenews.org/event/sl000026505/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T183000
DTEND;TZID=America/New_York:20260517T213000
DTSTAMP:20260408T052717
CREATED:20260401T175153Z
LAST-MODIFIED:20260401T175153Z
UID:10000384-1779042600-1779053400@www.atsconferencenews.org
SUMMARY:Feuding With Fibrosing ILD: Pathways to Timely Diagnosis and Care
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/feuding-with-fibrosing-ild-pathways-to-timely-diagnosis-and-care/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260517T190000
DTEND;TZID=America/New_York:20260517T213000
DTSTAMP:20260408T052717
CREATED:20260401T175152Z
LAST-MODIFIED:20260401T175152Z
UID:10000383-1779044400-1779053400@www.atsconferencenews.org
SUMMARY:Bridging Lived and Clinical Experiences: Patient and Pulmonologist Perspectives in IPF and PPF
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/bridging-lived-and-clinical-experiences-patient-and-pulmonologist-perspectives-in-ipf-and-ppf/
CATEGORIES:Evening Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T110500
DTEND;TZID=America/New_York:20260518T113500
DTSTAMP:20260408T052717
CREATED:20260401T175509Z
LAST-MODIFIED:20260401T182209Z
UID:10000426-1779102300-1779104100@www.atsconferencenews.org
SUMMARY:Raising the Bar with SURPASS-IPF: The First Phase 3 Head-to-Head Superiority Trial in IPF Testing Deupirfenidone vs. Pirfenidone
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/raising-the-bar-with-surpass-ipf-the-first-phase-3-head-to-head-superiority-trial-in-ipf-testing-deupirfenidone-vs-pirfenidone/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T113000
DTEND;TZID=America/New_York:20260518T120000
DTSTAMP:20260408T052717
CREATED:20260403T154946Z
LAST-MODIFIED:20260403T155413Z
UID:10000431-1779103800-1779105600@www.atsconferencenews.org
SUMMARY:Nasal High Flow: Does One Size Fit All?
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/nasal-high-flow-does-one-size-fit-all/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T113000
DTEND;TZID=America/New_York:20260518T123000
DTSTAMP:20260408T052717
CREATED:20260401T175300Z
LAST-MODIFIED:20260403T214052Z
UID:10000396-1779103800-1779107400@www.atsconferencenews.org
SUMMARY:Problem-Based Learning: Type 2 Inflammation in COPD
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/problem-based-learning-type-2-inflammation-in-copd-2/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T113000
DTEND;TZID=America/New_York:20260518T123000
DTSTAMP:20260408T052717
CREATED:20260401T175301Z
LAST-MODIFIED:20260401T175301Z
UID:10000397-1779103800-1779107400@www.atsconferencenews.org
SUMMARY:Starting at the Top: A Different Approach to Severe Asthma and CRSwNP
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/starting-at-the-top-a-different-approach-to-severe-asthma-and-crswnp/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T113500
DTEND;TZID=America/New_York:20260518T115500
DTSTAMP:20260408T052717
CREATED:20260403T181901Z
LAST-MODIFIED:20260403T192207Z
UID:10000433-1779104100-1779105300@www.atsconferencenews.org
SUMMARY:Radiology Round-Up: The Importance of HRCT in Interstitial Lung Diseases
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/radiology-round-up-the-importance-of-hrct-in-interstitial-lung-diseases/
CATEGORIES:Innovation Hubs
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T114500
DTEND;TZID=America/New_York:20260518T123000
DTSTAMP:20260408T052717
CREATED:20260401T175426Z
LAST-MODIFIED:20260403T185604Z
UID:10000398-1779104700-1779107400@www.atsconferencenews.org
SUMMARY:YUTREPIA®  (treprostinil) inhalation powder: a prostacyclin treatment for your PH-ILD patients
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/yutrepia%c2%acae-treprostinil-inhalation-powder-a-prostacyclin-treatment-for-your-ph-ild-patients/
CATEGORIES:Innovation Theaters
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260518T115500
DTEND;TZID=America/New_York:20260518T121500
DTSTAMP:20260408T052717
CREATED:20260401T175509Z
LAST-MODIFIED:20260403T192113Z
UID:10000427-1779105300-1779106500@www.atsconferencenews.org
SUMMARY:From Insight to Intervention: Future Clinical Pathways Enabled by CT-Based Non-Contrast Ventilation–Perfusion Pulmonary Mapping
DESCRIPTION:
URL:https://www.atsconferencenews.org/event/from-insight-to-intervention-future-clinical-pathways-enabled-by-ctaebased-non-contrast-ventilationaiperfusion-pulmonary-mapping/
CATEGORIES:Innovation Hubs
END:VEVENT
END:VCALENDAR